Canbridge Pharmaceuticals Inc
Company Profile
Business description
Canbridge Pharmaceuticals Inc is a biopharmaceutical company. It is committed to the research, development, and commercialization of biotech therapies targeting rare diseases and rare oncology. The company's core product in the rare oncology area CAN008, is a glycosylated CD95-Fc fusion protein being developed for the treatment of glioblastoma multiforme (GBM). In the rare disease area, the company have seven biologics and small molecules products and product candidates for the treatment of Hunter Syndrome (MPS II) and other lysosomal storage disorders (LSDs), complement mediated disorders, hemophilia A, metabolic disorders, and rare cholestatic liver diseases including ALGS, PFIC and BA. Its pipeline consists of biologics, small molecules, and gene therapy solutions and 13 drugs.
Contact
Building 21, No. 388 Xinping Street
Unit 18, 6th Floor, Suzhou Industrial Park
Suzhou
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
67
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,524.30 | 323.30 | -4.12% |
| CAC 40 | 7,017.50 | 257.45 | -3.54% |
| DAX 40 | 20,010.11 | 631.61 | -3.06% |
| Dow JONES (US) | 37,822.40 | 2,723.53 | -6.72% |
| FTSE 100 | 7,802.51 | 252.47 | -3.13% |
| HKSE | 19,828.30 | 3,021.51 | -13.22% |
| NASDAQ | 15,556.05 | 994.56 | -6.01% |
| Nikkei 225 | 31,136.58 | 2,644.00 | -7.83% |
| NZX 50 Index | 11,775.88 | 449.40 | -3.68% |
| S&P 500 | 5,041.94 | 32.14 | -0.63% |
| S&P/ASX 200 | 7,343.30 | 324.50 | -4.23% |
| SSE Composite Index | 3,096.58 | 245.43 | -7.34% |